Randomized trial · 2019

Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition.

Arkell TR, Lintzeris N, Kevin RC, Ramaekers JG, Vandrey R, Irwin C, Haber PS, McGregor IS.

Study design
Randomized trial
Population / model
Human
Published
2019-05-01
Journal
Psychopharmacology

From the author abstract

“CONCLUSIONS/INTERPRETATION Cannabis containing equivalent concentrations of CBD and THC appears no less impairing than THC-dominant cannabis, and in some circumstances, CBD may …”

A short attributed excerpt. Read the full abstract and original paper for methods, results and limitations.

Figures from the paper

Fig. 1 Order of events during experimental sessions. VAS visual analog scale, STAI State Trait Anxiety Inventory, DSST Digit Symbol Substitution Task, DAT Divided Attention Task, PASAT Paced Auditory Serial Addition Task, ADSES Adelaide Driving Self-Efficacy ScaleArkell TR, Lintzeris N, Kevin RC, Ramaekers JG, Vandrey R, Irwin C, Haber PS, McGregor IS. Psychopharmacology (2019). Original figure · CC BY · Resized for display.
Fig. 2 Mean (SEM) participant ratings of “Stoned”, “Strength of drug effect”, “Sedated”, “Liking of drug effect”, “Anxious” and “Confident to drive” assessed using 1-100mm visual analog scales after vaporization of placebo, THC-dominant, and THC/CBD-equivalent cannabis. All scales were unipolar except for “Liking of drug effect”. BL baselineArkell TR, Lintzeris N, Kevin RC, Ramaekers JG, Vandrey R, Irwin C, Haber PS, McGregor IS. Psychopharmacology (2019). Original figure · CC BY · Resized for display.
Citation and indexing details

PMID 31044290 · PMC6695367

Publication types: Journal Article; Randomized Controlled Trial

Topic tags: Psychiatry & cognition

Metadata checked 2026-11-04. Study design and model tags follow indexing and explicit abstract terms. Citation counts are not evidence of benefit. An available full text does not by itself permit image reuse.